¹³C breath tests in personalized medicine: fiction or reality?

References

• Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature456, 728–731 (2008).
   PubMed Web of Science ®Google Scholar
• Chanock S, Manolio T, Boehnke M et al. Replicating genotype–phenotype associations Nature447, 665–660 (2007).
   Google Scholar
• Lamberts S, Uitterlinden A. Genetic testing in clinical practice. Annu. Rev. Med.60, 431–442 (2009).
   PubMedGoogle Scholar
• Higgs J, Andrews J, Gurwitz D, Payne K, Newman W. Pharmacogenetics education in British medical schools. Genomic Med.2(3–4), 101–105 (2009).
   Google Scholar
• Shah R. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Phil. Trans. R. Soc. B360, 1617–1638 (2005).
   PubMed Web of Science ®Google Scholar
• Davies S. Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet? Hemotology2006, 111–117 (2006)
   Google Scholar
• Avigan M. Pharmacogenomic biomarkers of susceptibility to adverse drug reactions: just around the corner or pie in the sky? Per. Med.6(1), 67–78 (2009).
   PubMedGoogle Scholar
• Frueh F, Amur S, Mummaneni P et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy28(8), 992–999 (2008).
   PubMed Web of Science ®Google Scholar
• Dean CE. Personalized medicine: boon or budget-buster? Ann. Pharmacother.43(5), 958–962 (2009).
   PubMed Web of Science ®Google Scholar
• Leeder SJ, Spielberg SP. Personalized medicine: reality and reality checks. Ann. Pharmacother.43(5), 963–966 (2009).
   PubMedGoogle Scholar
• Griggs J. Personalized medicine: a perk of privilege? Clin. Pharmacol. Ther.86, 21–23 (2009).
   PubMedGoogle Scholar
• Zhou SF, Di YM, Chan E et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab.9, 738–784 (2008).
   PubMed Web of Science ®Google Scholar
• Malorye A. Is personalized medicine finally arriving? Nat. Biotechnol.26, 509–517 (2008).
   PubMedGoogle Scholar
• Lesko L. Personalized medicine: elusive dream or imminent reality? Clin. Pharmacol. Ther.81, 807–816 (2007).
   PubMed Web of Science ®Google Scholar
• Walk E. The role of pathologists in the era of personalized medicine. Arch. Pathol. Lab. Med.133, 605–610 (2009).
   PubMed Web of Science ®Google Scholar
• Ng PC, Zhao Q, Levy S, Strausberg R, Venter J. Individual genomes instead of race for personalized medicine. Clin. Pharmacol. Ther.84, 306–309 (2008).
   PubMed Web of Science ®Google Scholar
• Walko C, McLeod H. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat. Clin. Pract. Oncol.6, 153–162 (2009).
   PubMedGoogle Scholar
• Jonathan B. Overdevest J, Dan Theodorescu D, Lee J. Utilizing the molecular gateway: the path to personalized cancer management. Clin. Chem.55, 684–697 (2009).
   PubMedGoogle Scholar
• Gutman S, Kessler L. The US Food and Drug Administration perspective on cancer biomarker development. Nat. Rev. Cancer6, 565–571 (2006).
   PubMed Web of Science ®Google Scholar
• Sweeney G. Unravelling the mechanisms linking obesity to heart failure: the role of adipokines. Expert Rev. Endocrinol. Metab.4(2), 95–97 (2009).
   PubMedGoogle Scholar
• de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology34, 159–172 (2008).
   PubMedGoogle Scholar
• Pharmacogenomics and Personalized Medicine Series: Methods in Pharmacology and Toxicology. Cohen N (Ed.). Humana Press, NJ, USA, XVI, 509 (2008).
   Google Scholar
• Pauling L, Robinson A, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas–liquid partition chromatography. Proc. Natl Acad. Sci. USA68, 2374–2376 (1971).
   PubMed Web of Science ®Google Scholar
• Phillips N, Herrera J, Krishnan S, Zain M, Greenberg J, Cataneo R. Variation in volatile organic compounds in the breath of normal humans. J. Chromatogr. B Biomed. Sci. Appl.729, 75–88 (1999).
   PubMed Web of Science ®Google Scholar
• Lacroix M, Mosora F, Pontus M, Lefebvre P, Luyckz A, Lopez-Habib G. Glucose naturally labeled with carbon-13: use for metabolic studies in man. Science181, 445–446 (1973).
   PubMedGoogle Scholar
• Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefler S. The aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. Allergy Clin. Immunol.114, 1241–1256 (2004).
   Google Scholar
• Phillips M, Boehmer JP, Cataneo RN et al. Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). J. Heart Lung Transplant.23, 701–708 (2004).
   PubMedGoogle Scholar
• Graham D, Evans D Jr, Alpert L et al. Campylobacter pylori detected non-invasively by the (13)C-urea breath. Lancet1, 1174–1177 (1987).
   PubMed Web of Science ®Google Scholar
• Modak AS. Stable isotope breath tests in clinical medicine: a review. J. Breath Res.1, 014003 (2007).
   Google Scholar
• Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc.279, 1200–1205 (1998).
   PubMed Web of Science ®Google Scholar
• Alvarado I, Wong M, Licinio J. Advances in the pharmacogenomics of adverse drug reactions. Pharmacogenomics J.2, 273 (2002).
   PubMedGoogle Scholar
• Phillips K, Veenstra D, Oren E, Lee J, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J. Am. Med. Assoc.286, 2270–2279 (2002).
   Google Scholar
• Sikka R, Magauran B, Ulrich A, Shannon M. Bench to bedside: pharmacogenomics, adverse drug interactions, and the cytochrome P450 system. Acad. Emerg. Med.12, 1227–1235 (2005).
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N. Engl. J. Med.348, 529–537 (2003).
   PubMed Web of Science ®Google Scholar
• Kollek R, van Aken J, Feuerstein G, Schmedders M. Pharmacogenetics, adverse drug reactions and public health. Community Genet.9, 50–54 (2006).
   PubMedGoogle Scholar
• Evans W, McLeod H. Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med.348, 538–549 (2003).
   PubMed Web of Science ®Google Scholar
• van Puijenbroek E, Conemans J, van Grootheest K. Spontaneous ADR reports as a trigger for pharmacogenetic research: a prospective observational study in The Netherlands. Drug Saf.32(3), 255–264 (2009).
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Pirmohamed M. Adverse drug reactions and pharmacogenomics: recent advances. Per. Med.5(1), 11–23 (2008).
   PubMed Web of Science ®Google Scholar
• Murphy P, Sullivan H. Stable isotopes in pharmacokinetic studies. Annu. Rev. Pharmacol. Toxicol.20, 609–621 (1980).
   PubMed Web of Science ®Google Scholar
• Lappin G, Rowland M, Garner R. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol.2, 419–427 (2006).
   PubMed Web of Science ®Google Scholar
• Grant R, Wilkinson G. Drug metabolism and variability among patients in drug response. N. Engl. J. Med.352, 2211–2221 (2005).
   PubMedGoogle Scholar
• Schneider A, Caspary W, Saich R et al.13C-methacetin breath test shortened: 2-point-measurements after 15 minutes reliably indicate the presence of liver cirrhosis. J. Clin. Gastroenterol.41, 33–37 (2007).
   PubMed Web of Science ®Google Scholar
• Lalazar G. The point of care 13C methacetin breath test accurately predicts long-term prognosis in patients with chronic liver disease: a noninvasive liver function test. Presented at: Digestive Disease Week 2009. IL, USA, 30 May–4 June 2009 (Abstract S1837).
   Google Scholar
• Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci.25, 193–200 (2004).
   PubMed Web of Science ®Google Scholar
• Leeder JS, Pearce R, Gaedigk A, Modak A, Rosen D. Evaluation of the [13C]-DM breath test to assess CYP2D6 phenotype. J. Clin. Pharm.48, 2041–2051 (2008).
   Google Scholar
• Desta Z, Modak A, Nguyen P et al. Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. JPET329, 297–305 (2009).
   PubMedGoogle Scholar
• Mattison L, Hany Ezzeldin H, Carpenter M, Modak A, Johnson M, Diasio R. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin. Can. Res.10, 2652–2659 (2004).
   PubMed Web of Science ®Google Scholar
• Mattison L, Fourie J, Renee A et al. Racial differences in dihydropyrimidine dehydrogenase activity: increased prevalence of DPD deficiency in African Americans compared to Caucasians. Clin. Can. Res.12, 5491–5495 (2006).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Owaki T, Sumi S et al. Usefulness of uracil loading test for detecting 5-fluorouracil metabolic enzyme deficiencies in humans. Int. J. Clin. Oncol.5(5), 171–173 (2000).
   Google Scholar
• Gutman S, Hackett J. Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side. Pharmacogenomics7(8), 1223–1227 (2006).
   PubMed Web of Science ®Google Scholar
• Hinman L, Spear B, Tsuchihashi Z et al. Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop. Pharmacogenomics10(1), 127–136 (2009).
   PubMed Web of Science ®Google Scholar
• Rebsamen MC, Desmeules J, Daali Y et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J.9, 34–41 (2009).
   PubMed Web of Science ®Google Scholar
• Williams A, Andersson T, Andersson TB et al. PhRMA white paper on ADME pharmacogenomics. J. Clin. Pharmacol.48, 849–889 (2008).
   PubMed Web of Science ®Google Scholar
• Powell J, Gobburu J. Pharmacometrics at FDA: evolution and impact on decisions. Clin. Pharmacol. Ther.82, 97–102 (2007).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N. Engl. J. Med.358(6), 637–639 (2008).
   PubMed Web of Science ®Google Scholar
• Jørgensen JT. From blockbuster medicine to personalized medicine. Per. Med.5(1), 55–63 (2008).
   PubMed Web of Science ®Google Scholar
• Fackler J, McGuire A. Paving the way to personalized genomic medicine: steps to successful implementation. Curr. Pharmacogenomics Person. Med.7(2), 125–132 (2009).
   PubMedGoogle Scholar
• Evans B. Distinguishing product and practice regulation in personalized medicine. Clin. Pharmacol. Ther.81, 288–293 (2007).
   PubMedGoogle Scholar
• Carlson R. The disruptive nature of personalized medicine technologies: implications for the health care system. Public Health Genomics12(3), 180–184 (2009).
   PubMedGoogle Scholar
• Newman W, Payne K. Removing barriers to a clinical pharmacogenetics service. Per. Med.5(5), 471–480 (2008).
   PubMed Web of Science ®Google Scholar
• Beutow K. An infrastructure for interconnecting research institutions. Drug Discovery Today14, 605–610 (2009).
   PubMedGoogle Scholar
• Ioannidis J. Limits to forecasting in personalized medicine: an overview. Int. J. Forecast. DOI: 10.1016/j.ijforecast.2009.05.003 (2009) (Epub ahead of print).
   Google Scholar